Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Massachusetts General Hospital
University of California, Irvine
Fred Hutchinson Cancer Center
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Duke University
University of Kentucky
Northwestern University
Fred Hutchinson Cancer Center